Skip to content

Comparision of clinical efficacy of Intravenous acetaminophen vs ketorolac to relieve pain in renal colic

Comparision of clinical efficacy of Intravenous acetaminophen vs ketorolac to relieve pain in renal colic

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015090223855N1
Enrollment
120
Registered
2015-10-27
Start date
2015-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Renal Colic. Urinary calculus, unspecified

Interventions

Intervention 1: Intervention group: patients will receive 30 mg intravenous ketorolac tromethamine (brand name : ketorolac ,Caspian Tamin Pharmaceutical Company) within 15 seconds. Intervention 2: Con
Treatment - Drugs
Intervention group: patients will receive 30 mg intravenous ketorolac tromethamine (brand name : ketorolac ,Caspian Tamin Pharmaceutical Company) within 15 seconds.
Control group: patients will receive 1 gram intravenous paracetamol (brand name : Apotel) infused in 100 ml normal saline within 15 minutes.

Sponsors

Vice- Chancellor for Research, Semnan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients will eligible for inclusion with a history of unilateral abdominal or flank pain that the treating emergency physicians suspect to be renal colic, with ultrasonography or CT Scan or intravenous pyelography (IVP) findings consistent with the diagnosis of renal colic or passage of the calculus. Only patients displaying at least a visual analog scale (VAS) =30/100 will include. Patients can not be include if they have a history of peptic ulcer disease, asthma, bleeding disorder (including the use of oral anticoagulant), impaired renal or hepatic function, suspected hypersensivity to aspirin or NSAID or paracetamol, and if they are pregnant and breast-feeding women. Patients can not be include if they have received painkillers within 6 hours before presentation and if they are younger than 18 and greater than 55 years old.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Level of pain. Timepoint: before treatment initiation and sequentially at 20,40,60 minutes. Method of measurement: Visual Analogue Scale.

Secondary

MeasureTime frame
Heart Rate. Timepoint: before treatment initiation and sequentially at 20,40,60 minutes. Method of measurement: Radial Pulse.;Blood pressure. Timepoint: before treatment initiation and sequentially at 20,40,60 minutes. Method of measurement: sphygmomanometer.;Body temprature. Timepoint: before treatment initiation and sequentially at 20,40,60 minutes. Method of measurement: Thermometer(axillary).;Respiratory rate. Timepoint: before treatment initiation and sequentially at 20,40,60 minutes. Method of measurement: Physical examination.;Size of renal calculi. Timepoint: after pain relief. Method of measurement: imaging findings.;Location of renal calculi. Timepoint: after pain relief. Method of measurement: imaging findings.;Paracetamol side effects. Timepoint: in all the time in care. Method of measurement: questionnaire and physical examination.;Ketorolac side effects. Timepoint: in all the time in care. Method of measurement: questionnaire and physical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Davood Arab

Semnan University of Medical Sciences

drdavoodarab@semums.ir+98 23 3343 7830

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026